Idiopathic Thrombocytopenic Purpura Clinical Trials

67 clinical trials for Idiopathic Thrombocytopenic Purpura across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) — RECRUITING · PHASE2
• Platelet activation and procoagulant platelets in patients with immune thrombocytopenia: a prospective study — RECRUITING
• Safety and Efficacy of Fecal Microbiota Transplantation — RECRUITING · NA
• EXTEND (Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag study — COMPLETED · PHASE4
• An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias — ACTIVE_NOT_RECRUITING · PHASE1
• Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) — COMPLETED · PHASE2
• A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 — COMPLETED · PHASE3
• Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients — COMPLETED · PHASE2
• Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients — COMPLETED · PHASE3
• At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions — COMPLETED
• Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP — COMPLETED · PHASE3
• Prevalence of Gaucher Disease in Hematological Routine Practice – from Thrombocytopenia to Diagnosis of Gaucher Disease (PRAGMATIC-Diagnosis) — OTHER
• An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP — COMPLETED · PHASE3
• AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy — COMPLETED · PHASE3
• P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura — COMPLETED · PHASE3
• Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura — COMPLETED · PHASE3
• AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy — COMPLETED · PHASE3
• Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) — COMPLETED · PHASE4
• Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim — COMPLETED · PHASE2
• Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient — COMPLETED · PHASE3
• Investigation on a Dynamic Cohort of Italian Patients With Active ITP — OTHER
• Study of Platelets Sialylation by Flow Cytometry for the Differential Diagnosis of ICT — COMPLETED
• The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP. — COMPLETED · NA
• Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases — COMPLETED · PHASE2
• Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level — COMPLETED
• Assessment of Quality of Life of Children With Chronic Idiopathic Thrombocytopenic Purpura (Kid's ITP Tools) — OTHER
• Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) — COMPLETED · PHASE2
• Sirolimus for Autoimmune Disease of Blood Cells — COMPLETED · PHASE1
• Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind? — OTHER · NA
• Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP) — WITHDRAWN
• The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP) — COMPLETED · PHASE3
• Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) — COMPLETED · PHASE3
• Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP — TERMINATED · PHASE1
• A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone — WITHDRAWN · PHASE2
• Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003 — COMPLETED · PHASE2
• A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) — TERMINATED · PHASE3
• Post-Authorisation Surveillance Safety study with Flebogamma DIF100 mg/ml and Flebogamma DIF50 mg/ml — OTHER
• IGIV Study for Chronic ITP Patients Ages 3-70 — COMPLETED · PHASE3
• Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients — COMPLETED · PHASE3
• Single Incision Versus Standard Laparoscopic Splenectomy — WITHDRAWN · NA
• Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients — COMPLETED · PHASE3
• All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) — WITHDRAWN · PHASE3
• rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP — COMPLETED · PHASE3
• Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) — COMPLETED · PHASE3
• rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP — COMPLETED · PHASE3
• Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) — WITHDRAWN · PHASE3
• MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP — WITHDRAWN · PHASE2
• Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP) — TERMINATED · PHASE1
• Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. — COMPLETED · PHASE3
• A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. — COMPLETED · PHASE2

Refine this search